Key Takeaways
- • Drug development and discovery emerges as Bain Capital's priority AI investment thesis, with Devin O'Reilly citing companies like Isomorphic Labs as exemplary players in solving drug development complexity.
- • Bain and Thoma Bravo executed a merger between clinical trial vendors Suvoda and Greenphire earlier in 2025, signaling consolidation activity in health AI infrastructure.
- • Valuation caution dominates Bain's investment approach—O'Reilly expresses skepticism about elevated early-stage health tech valuations, noting his firm typically targets investments using profitability multiples and revenue multiples for earlier-stage opportunities.
- • Exit environment for scaled PE-backed health assets has normalized, with public markets becoming viable again; Bain took Waystar, a revenue cycle software company, public last year with strong post-IPO performance.
- • Private equity investors are expected to expand their role in health AI as generative AI entrants mature, positioning firms like Bain to shape consolidation and scaling across the sector.
Summary
Devin O'Reilly, head of healthcare investing for Bain Capital's North America private equity practice, outlined a focused thesis on health AI investing centered on drug development and discovery—a space that extends beyond revenue cycle management and billing optimization, where many AI applications currently concentrate. O'Reilly highlighted emerging companies like Isomorphic Labs as exemplars of the technological progress required to address drug development complexity, signaling Bain's confidence in this segment's investment potential.
The firm has already moved on this thesis in 2025. Bain Capital and Thoma Bravo co-led a merger between clinical trial technology vendors Suvoda and Greenphire earlier this year, consolidating two platforms within the health AI infrastructure ecosystem. This transaction reflects the broader thesis that private equity investors will increasingly play a central role in health AI as generative AI companies mature and move beyond venture-stage development.
On valuation dynamics, O'Reilly adopted a notably cautious tone regarding the broader health tech investment landscape. While acknowledging that "extraordinary valuations" exist primarily at the venture stage, he expressed personal skepticism about whether early-stage health tech multiples are justified long-term. Bain's investment discipline targets profitability multiples for mature opportunities and revenue multiples selectively for earlier-stage companies—a more conservative approach that diverges from the aggressive venture pricing that has dominated recent years.
The exit environment for scaled, PE-backed health assets has normalized significantly. O'Reilly pointed to Waystar, a revenue cycle software platform from Bain's portfolio taken public last year, as evidence that public markets remain a viable exit channel. Waystar's strong post-IPO performance validates the broader strategy of building and scaling health tech platforms through private equity ownership before public market deployment. This normalization suggests improved conditions for realizing returns on maturing health tech investments compared to the compressed exit window of prior years.
The firm has already moved on this thesis in 2025. Bain Capital and Thoma Bravo co-led a merger between clinical trial technology vendors Suvoda and Greenphire earlier this year, consolidating two platforms within the health AI infrastructure ecosystem. This transaction reflects the broader thesis that private equity investors will increasingly play a central role in health AI as generative AI companies mature and move beyond venture-stage development.
On valuation dynamics, O'Reilly adopted a notably cautious tone regarding the broader health tech investment landscape. While acknowledging that "extraordinary valuations" exist primarily at the venture stage, he expressed personal skepticism about whether early-stage health tech multiples are justified long-term. Bain's investment discipline targets profitability multiples for mature opportunities and revenue multiples selectively for earlier-stage companies—a more conservative approach that diverges from the aggressive venture pricing that has dominated recent years.
The exit environment for scaled, PE-backed health assets has normalized significantly. O'Reilly pointed to Waystar, a revenue cycle software platform from Bain's portfolio taken public last year, as evidence that public markets remain a viable exit channel. Waystar's strong post-IPO performance validates the broader strategy of building and scaling health tech platforms through private equity ownership before public market deployment. This normalization suggests improved conditions for realizing returns on maturing health tech investments compared to the compressed exit window of prior years.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.